title: Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report.
abstract: Pancreatic acinar cell carcinoma is an uncommon neoplasm of the exocrine pancreas associated with a poor prognosis, especially when found to be metastatic. Since there are a lack of large studies and prospective, randomized data, no consensus treatment guidelines are available. Here, we report a case of a patient with recurrent metastatic acinar cell carcinoma involving the liver who had presented initially with pancreatic panniculitis. She received chemotherapy with capecitabine and oxaliplatin prior to resection of her primary tumor and liver metastases, after which she experienced a 30 months recurrence-free survival. Upon relapse, she was treated with a combination of capecitabine and oxaliplatin followed by maintenance capecitabine. Now, more than seven years after initial diagnosis, the patient remains stable without evidence of active disease. This case highlights the possibility of therapeutic success even for a patient initially deemed unresectable due to a poor performance status who responded to fluoropyrimidine-based therapy.
authors.affiliation: The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit Number: 426, Houston, TX 77030, USA.
authors.forename: Sarah F
authors.initials: SF
authors.lastname: Jauch
authors.affiliation: The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit Number: 426, Houston, TX 77030, USA.
authors.forename: Van K
authors.initials: VK
authors.lastname: Morris
authors.affiliation: The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit Number: 426, Houston, TX 77030, USA.
authors.forename: Corey T
authors.initials: CT
authors.lastname: Jensen
authors.affiliation: The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit Number: 426, Houston, TX 77030, USA. Electronic address: akaseb@mdanderson.org.
authors.forename: Ahmed O
authors.initials: AO
authors.lastname: Kaseb
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000069287:Capecitabine / Q000627:therapeutic use; D018267:Carcinoma, Acinar Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000069287:Capecitabine
keywords: ACC; Acinar cell; Maintenance capecitabine; Metastatic pancreatic cancer; Pancreatic panniculitis; XELOX chemotherapy